Timothy Schulz-utermoehl

Director @ DMPK Consulting Limited

About

HEALTHCARE All aspects of Preclinical Development and DMPK including project management. Focus is on in vitro ADME , pharmacokinetics and drug transporters. Strong experience in providing advice and acting as consultant to project related DDIs (metabolism and transporter based) and reactive metabolites (assay setup, in vivo models). Specialties include DMPK, in vitro early and late ADME, project management, metabolism and transporters, drug interactions, reactive metabolites, discovery and development process, general management of graduates and postgraduates, leadership of staff, project management, scientific assay development; outsourcing to CROs, GLP

Country

City

United Kingdom

Industry

Biotechnology

Skill

DMPK, Drug Interactions, Project Management, Drug Discovery, GLP, ADME, In Vitro, Clinical Development, In Vivo, Drug Metabolism, Drug Development, Bioanalysis, LC-MS, Assay Development, Toxicology, Pharmacokinetics, Lifesciences, CRO, Life Sciences, Good Laboratory Practice (GLP)

Experience

Director

DMPK Consulting Limited

2020-1 - Present · 6 yrs 9 mos

United Kingdom

Helping academia and biotech companies with their DMPK and Preclinical Development needs.

Preclinical Lead

TheraCryf

2025-4 - Present · 1 yr 6 mos

Alderley Edge

Leading and Managing the IND-enabling studies for a Lead Program

DMPK Lead

Kasvu Therapeutics

2023-10 - Present · 3 yrs

Helsinki

Kasvu Therapeutics are developing first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered. Potent, rapid-acting and long-lasting without hallucinations.

DMPK Lead

Lario Therapeutics

2023-6 - Present · 3 yrs 4 mos

Edinburgh

Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease.

Head of Preclinical Development

Pheno Therapeutics Ltd

2023-10 - Present · 3 yrs

Head of DMPK

Pheno Therapeutics Ltd

2022-11 - 2023-9 · 11 mos

Edinburgh, Scotland, United Kingdom

Based in Edinburgh and positioned to deploy the founders' world-leading expertise in phenotypic screening, stem cell technology and myelin biology, Pheno aims to discover and develop small molecule therapeutics that promote remyelination for a variety of unmet medical needs.

Co-Founder

AUEY Medicines

2026-5 - Present · 5 mos

United Kingdom

A new startup that is directing its efforts towards discovering and developing a new class of mutation-agnostic oral small molecule therapeutics for Retinitis Pigmentosa.

Co-Founder

Pencil Biosciences Limited

2019-11 - Present · 6 yrs 11 mos

Alderley Park, United Kingdom

An exciting VC backed biotech that is developing a proprietary RNA guided gene editing by design platform technology - re-imagining gene editing from the ground up. www.pencilbiosciences.com

Co-founder and Scientific Advisor

Pandeia Therapeutics

2023-1 - 2026-4 · 3 yrs 4 mos

Pandeia was acquired by a mid-cap pharmaceutical company in December 2022. Continued support for the GPR88 program as it reaches the clinic.

Co-Founder and Chief Operating Officer

Pandeia Therapeutics

2020-1 - 2023-1 · 3 yrs 1 mo

Oxford and Alderley Park

Pandeia is developing first and best in class GPR88 agonists to treat the debilitating symptoms of Huntington’s disease. Co-founded and raised equity finance to build the company to a value inflection point